These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35738166)

  • 1. Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma.
    Wen R; Lin P; Wu Y; Yin H; Huang W; Guo D; Peng Y; Liu D; He Y; Yang H
    Eur J Radiol; 2022 Sep; 154():110415. PubMed ID: 35738166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Yang J; Zhang YH; Li JW; Shi YY; Huang JY; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Dec; 26(46):7325-7337. PubMed ID: 33362387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.
    Huang XW; Huang Y; Chen LD; Wang Z; Yang Z; Liu JY; Xie XY; Lu MD; Shen SL; Wang W
    J Med Ultrason (2001); 2018 Apr; 45(2):231-241. PubMed ID: 29052791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.
    Vidili G; Arru M; Solinas G; Calvisi DF; Meloni P; Sauchella A; Turilli D; Fabio C; Cossu A; Madeddu G; Babudieri S; Zocco MA; Iannetti G; Di Lembo E; Delitala AP; Manetti R
    World J Gastroenterol; 2022 Jul; 28(27):3488-3502. PubMed ID: 36158272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
    Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.
    Xian MF; Huang Y; Xie WX; Pan KM; Zeng D; Huang H; Li MD; Xie XY; Kuang M; Lu MD; Chen LD; Wang W
    AJR Am J Roentgenol; 2022 Jul; 219(1):76-85. PubMed ID: 34910538
    [No Abstract]   [Full Text] [Related]  

  • 7. Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies.
    Wen R; Huang F; Lin P; Gao R; Pang J; Wu Y; Yin H; Tang Z; Ma Z; He Y; Yang H
    Abdom Radiol (NY); 2023 Dec; 48(12):3688-3695. PubMed ID: 37726380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
    Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
    Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
    Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
    Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound.
    Chen LD; Ruan SM; Liang JY; Yang Z; Shen SL; Huang Y; Li W; Wang Z; Xie XY; Lu MD; Kuang M; Wang W
    World J Gastroenterol; 2018 Sep; 24(33):3786-3798. PubMed ID: 30197484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.
    Jiang H; Song B; Qin Y; Chen J; Xiao D; Ha HI; Liu X; Oloruntoba-Sanders O; Erkanli A; Muir AJ; Bashir MR
    Eur Radiol; 2021 Jun; 31(6):3638-3648. PubMed ID: 33245494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Value of CEUS LI-RADS combined with AFP in early diagnosis of hepatocellular carcinoma in low- and high-risk patients.
    Wu Y; Chen Y; Wei L; Ding Z; Zhao S; Bao S; Tang J; Li H; Liu J; Zhu S
    J Cancer Res Ther; 2024 Aug; 20(4):1274-1283. PubMed ID: 38958652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-parameter intrahepatic cholangiocarcinoma scoring system based on modified contrast-enhanced ultrasound LI-RADS M criteria for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
    Wang LF; Guan X; Shen YT; Zhou BY; Sun YK; Li XL; Yin HH; Lu D; Ye X; Hu XY; Yang DH; Xia HS; Wang X; Lu Q; Han H; Xu HX; Zhao CK;
    Abdom Radiol (NY); 2024 Feb; 49(2):458-470. PubMed ID: 38225379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation between combined hepatocellular carcinoma and hepatocellular carcinoma: comparison of diagnostic performance between ultrasomics-based model and CEUS LI-RADS v2017.
    Li CQ; Zheng X; Guo HL; Cheng MQ; Huang Y; Xie XY; Lu MD; Kuang M; Wang W; Chen LD
    BMC Med Imaging; 2022 Mar; 22(1):36. PubMed ID: 35241004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An assessment of liver lesions using a combination of CEUS LI-RADS and AFP.
    Li CQ; Huang H; Ruan SM; Hu HT; Xian MF; Xie XY; Lu MD; Kuang M; Wang Y; Chen LD
    Abdom Radiol (NY); 2022 Apr; 47(4):1311-1320. PubMed ID: 35122491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast-Enhanced Ultrasound for Differentiation Between Poorly Differentiated Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Guo HL; Zheng X; Cheng MQ; Zeng D; Huang H; Xie XY; Lu MD; Kuang M; Wang W; Xian MF; Chen LD
    J Ultrasound Med; 2022 May; 41(5):1213-1225. PubMed ID: 34423864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.
    Horvat N; Nikolovski I; Long N; Gerst S; Zheng J; Pak LM; Simpson A; Zheng J; Capanu M; Jarnagin WR; Mannelli L; Do RKG
    Abdom Radiol (NY); 2018 Jan; 43(1):169-178. PubMed ID: 28765978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Microvascular Invasion in Combined Hepatocellular-Cholangiocarcinoma Based on Pre-operative Clinical Data and Contrast-Enhanced Ultrasound Characteristics.
    Chen Y; Lu Q; Zhu Y; Huang B; Dong Y; Wang W
    Ultrasound Med Biol; 2022 Jul; 48(7):1190-1201. PubMed ID: 35397928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiating malignant and benign focal liver lesions in children using CEUS LI-RADS combined with serum alpha-fetoprotein.
    Jiang ZP; Zeng KY; Huang JY; Yang J; Yang R; Li JW; Qiu TT; Luo Y; Lu Q
    World J Gastroenterol; 2022 Jun; 28(21):2350-2360. PubMed ID: 35800178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.